RX Biosyent Inc

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today released a summary of its 2009
first quarter financial results.


Total Sales in the three months ending March 31, 2009 were $107,052, down from
$287,997 in the first quarter of 2008. The first quarter was impacted by general
recessionary conditions in the economy, higher than normal customer inventories
of Protect-It(R) and cold weather in the Canadian prairie region which is a
natural deterrent to stored grain infestation.


Gross Margins decreased from 60.2% in the first quarter of 2008, to 39.6% in the
first quarter of 2009 primarily due to the selling mix of lower margin products.
Management expects that greater sales of higher margin products in the second
quarter will see margins improve to more historic levels.


The Company incurred a loss of ($168,197) in the first quarter of 2009 compared
to a loss of ($74,067) in the first quarter of 2008.


Total negative cash flow for the first quarter 2009 was ($185,625) versus a
negative cash flow of ($247,203) in the prior year period.


Full details of 2009 quarter one results and Financial Statements and
Management's Discussion & Analysis have been posted on sedar.com.


BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source
products that have been successfully developed and proven to be safe and
effective; manage these products through the regulatory process and product
registration (approval); and once approved, market these products in Canada.
These pharmaceuticals will compete in both the branded and generic market
segments and will not require further product development investment other than
regulatory costs.


BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly
owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences
pharmaceutical products and markets these products in Canada. Wholly owned
BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy
business marketing bio and health friendly non-chemical insecticides. BioSyent
common shares are listed for trading on the TSX Venture Exchange (TSXV) under
the symbol RX.


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2024 to Jul 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Jul 2023 to Jul 2024